Product Details
| Alternative Name: | Interleukin-35, EBI3:IL-12A, IL-27B:CLMF p35 |
| |
| MW: | ~85kDa |
| |
| Source: | Produced in HEK 293 cells. Human EBI3 (aa 21-229) linked to human IL-12A (aa 23-219) via the linker GGGSGGGSGGGSGGGS is fused at the C-terminus to the Fc portion of human IgG1 and a FLAG®-tag. |
| |
| UniProt ID: | Q14213 (IL-27B), P29459 (IL-21A) |
| |
| Concentration: | 0.1mg/ml after reconstitution. |
| |
| Formulation: | Lyophilized. Contains PBS. |
| |
| Purity: | ≥95% (SDS-PAGE) |
| |
| Endotoxin Content: | <0.1EU/µg purified protein (LAL test; Associates of Cape Cod). |
| |
| Reconstitution: | Reconstitute with 100µl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum or a carrier protein. |
| |
| Shipping: | Blue Ice |
| |
| Short Term Storage: | +4°C |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Stable for at least 6 months after receipt when stored at -20°C. |
| |
| Handling: | Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and store at -20°C. |
| |
| Scientific Background: | EBI3 (Epstein-Barr virus-induced gene 3 protein; EBV-induced gene 3 protein; IL-27B; IL-27 subunit β) and IL-12A (IL-12 subunit p35; CLMF p35) form the heterodimeric cytokine IL-35 (interleukin-35) involved in T cell regulation. IL-35 is highly expressed in regulatory T cell (Treg) but not in effector or naive T cells. IL-35 is required for the suppressive function of T-reg in vitro and in vivo. |
| |
| Technical Info/Product Notes: | Historical data has shown that IL-35 binds to IL-12Rß2, and it has been demonstrated in the literature to inhibit mononuclear cell proliferation.
FLAG is a registered trademark of Sigma-Aldrich Co. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Product Literature References
IL-35 Inhibits Angiogenesis through VEGF/Ang2/Tie2 Pathway in Rheumatoid Arthritis: S. Jiang, et al.; Cell. Physiol. Biochem.
40, 1105 (2016),
Abstract;
IL-27 induces the expression of IDO and PD-L1 in human cancer cells: G. Carbotti, et al.; Oncotarget
6, 43267 (2015),
Abstract;
Full Text
Interleukin-35 Inhibits Endothelial Cell Activation by Suppressing MAPK-AP-1 Pathway: X. Sha, et al.; J. Biol. Chem.
290, 19307 (2015),
Application(s): Cell culture,
Abstract;
Pro-inflammatory effects of interleukin-35 in rheumatoid arthritis: M. Filková, et al.; Cytokine
73, 36 (2015),
Application(s): Cell Culture: IHC, IF used to analyze IL-35 in PBMCs,
Abstract;
Interleukin-27 is a potent inhibitor of cis HIV-1 replication in monocyte-derived dendritic cells via a type I interferon-independent pathway: Q. Chen, et al.; PLoS One
8, e59194 (2013),
Application(s): Treatment of monocytes-derived dendritic cells,
Abstract;
Full Text
Regulatory T-Cell (Treg) hybridoma as a novel tool to study Foxp3 regulation and Treg fate: R. Sharma, et al.; J. Autoimmun.
37, 113 (2011),
Abstract;
Human rhinoviruses induce IL-35-producing Treg via induction of B7-H1 (CD274) and sialoadhesin (CD169) on DC: M. Seyerl, et al.; Eur. J. Immunol.
40, 321 (2010),
Abstract;
General Literature References
IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells: W. Niedbala, et al.; Eur. J. Immunol.
37, 3021 (2007),
Abstract;
Full Text
The inhibitory cytokine IL-35 contributes to regulatory T-cell function: L.W. Collison, et al. ; Nature
450, 566 (2007),
Abstract;
Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin: O. Devergne, et al.; PNAS
94, 12041 (1997),
Abstract;
Full Text
Related Products
